MHRA response to EU exit no-deal legislative proposals consultation

Following the outcome of the EU referendum, the Medicines and Healthcare products Regulatory Agency (MHRA) says it is working closely with the government to analyze the best options and opportunities available for the safe and effective regulation of medicines and medical devices in the UK.

Noting that the UK is leaving the European Union on March 29, 2019, it states: “We remain focused on delivering the deal that we have negotiated with the EU. However, as a responsible government, it is right that we continue to prepare for all scenarios and provide information so that other organisations can do the same.

Following its consultation on how medicines, medical devices and clinical trials would be regulated in a no-deal scenario, the MHRA has issued updated guidance setting out the UK’s proposed arrangements for regulation post March 29 with no deal.